Restart Life Sciences Corp. (HEAL.CN) Research

Operating internationally through its various subsidiaries, Restart Life Sciences Corp. functions as a biotechnology firm. Its core endeavors include the creation of natural therapeutic remedies tailored for individuals with autism spectrum disorder, the development of health-promoting foods designed for comprehensive mind and body wellness, and the execution of a psilocybin clinical trial aimed at fragile X syndrome. Founded in 2004 and based in Vancouver, Canada, the company adopted its current name in November 2024, having previously been known as Nova Mentis Life Science Corp.

Market snapshot

Symbol
HEAL.CN
Price
$0.09
Day change
0.00%
Market cap
$3.3M
P/E ratio
-1.06x
52-week range
0.065-0.135
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Algernon Pharmaceuticals Inc. (AGN.CN)
  • Appili Therapeutics Inc. (APLI.TO)
  • Aptose Biosciences Inc. (APS.TO)
  • CordovaCann Corp. (CDVA.CN)
  • City View Green Holdings Inc. (CVGR.CN)
  • Kane Biotech Inc. (KNE.V)
  • Doseology Sciences Inc. (MOOD.CN)
  • Revive Therapeutics Ltd. (RVV.CN)

Open Restart Life Sciences Corp. (HEAL.CN) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.